Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2007 2
2008 1
2009 2
2010 1
2011 3
2012 2
2014 4
2015 2
2016 3
2017 4
2018 3
2019 2
2020 8
2021 33
2022 20
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.
Grigoryan L, Feng Y, Bellusci L, Lai L, Wali B, Ellis M, Yuan M, Arunachalam PS, Hu M, Kowli S, Gupta S, Maysel-Auslender S, Maecker HT, Samaha H, Rouphael N, Wilson IA, Moreno AC, Suthar MS, Khurana S, Pillet S, Charland N, Ward BJ, Pulendran B. Grigoryan L, et al. Among authors: lai l. Sci Immunol. 2024 Apr 5;9(94):eadi8039. doi: 10.1126/sciimmunol.adi8039. Epub 2024 Apr 5. Sci Immunol. 2024. PMID: 38579013
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
Happe M, Hofstetter AR, Wang J, Yamshchikov GV, Holman LA, Novik L, Strom L, Kiweewa F, Wakabi S, Millard M, Kelley CF, Kabbani S, Edupuganti S, Beck A, Kaltovich F, Murray T, Tsukerman S, Carr D, Ashman C, Stanley DA, Ploquin A, Bailer RT, Schwartz R, Cham F, Tindikahwa A, Hu Z, Gordon IJ, Rouphael N, Houser KV, Coates EE, Graham BS, Koup RA, Mascola JR, Sullivan NJ, Robb ML, Ake JA, Lyke KE, Mulligan MJ, Ledgerwood JE, Kibuuka H; VRC 208 and RV 422 study team. Happe M, et al. NPJ Vaccines. 2024 Mar 29;9(1):67. doi: 10.1038/s41541-024-00833-z. NPJ Vaccines. 2024. PMID: 38553525 Free PMC article.
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults.
Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, Lai L, Tsong R, Kao CM, Raabe V, El Sahly HM, Keitel WA, Whitaker JA, Smith MJ, Schmader KE, Swamy GK, Abate G, Winokur P, Buchanan W, Cross K, Wegel A, Xu Y, Yildirim I, Kamidani S, Rouphael N, Roberts PC, Mulligan MJ, Anderson EJ. Rostad CA, et al. Among authors: lai l. Clin Infect Dis. 2024 Mar 27:ciae173. doi: 10.1093/cid/ciae173. Online ahead of print. Clin Infect Dis. 2024. PMID: 38537255
XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants.
Jain S, Kumar S, Lai L, Linderman S, Malik AA, Ellis ML, Godbole S, Solis D, Sahoo MK, Bechnak K, Paredes I, Tanios R, Kazzi B, Dib SM, Litvack MB, Wimalasena ST, Ciric C, Rostad C, West R, Teng IT, Wang D, Edupuganti S, Kwong PD, Rouphael N, Pinsky BA, Douek DC, Wrammert J, Moreno A, Suthar MS. Jain S, et al. Among authors: lai l. bioRxiv [Preprint]. 2024 Feb 5:2024.02.03.578771. doi: 10.1101/2024.02.03.578771. bioRxiv. 2024. PMID: 38370837 Free PMC article. Preprint.
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
Blazevic A, Edwards RL, Xia M, Eickhoff CS, Hamzabegovic F, Meza KA, Ning H, Tennant J, Mosby KJ, Ritchie JC, Girmay T, Lai L, McCullough M, Beck A, Kelley C, Edupuganti S, Kabbani S, Buchanan W, Makhene MK, Voronca D, Cherikh S, Goll JB, Rouphael NG, Mulligan MJ, Hoft DF. Blazevic A, et al. Among authors: lai l. J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093/infdis/jiad441. Online ahead of print. J Infect Dis. 2023. PMID: 38019956
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
Valanparambil RM, Lai L, Johns MA, Davis-Gardner M, Linderman SL, McPherson TO, Chang A, Akhtar A, Gamarra ELB, Matia H, McCook-Veal AA, Switchenko J, Nasti TH, Green F, Saini M, Wieland A, Pinsky BA, Solis D, Dhodapkar MV, Carlisle J, Ramalingam S, Ahmed R, Suthar MS. Valanparambil RM, et al. Among authors: lai l. NPJ Vaccines. 2023 Nov 21;8(1):179. doi: 10.1038/s41541-023-00779-8. NPJ Vaccines. 2023. PMID: 37990024 Free PMC article.
Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera.
Mühlemann B, Wilks SH, Baracco L, Bekliz M, Carreño JM, Corman VM, Davis-Gardner ME, Dejnirattisai W, Diamond MS, Douek DC, Drosten C, Eckerle I, Edara VV, Ellis M, Fouchier RAM, Frieman M, Godbole S, Haagmans B, Halfmann PJ, Henry AR, Jones TC, Katzelnick LC, Kawaoka Y, Kimpel J, Krammer F, Lai L, Liu C, Lusvarghi S, Meyer B, Mongkolsapaya J, Montefiori DC, Mykytyn A, Netzl A, Pollett S, Rössler A, Screaton GR, Shen X, Sigal A, Simon V, Subramanian R, Supasa P, Suthar M, Türeli S, Wang W, Weiss CD, Smith DJ. Mühlemann B, et al. Among authors: lai l. bioRxiv [Preprint]. 2023 Sep 27:2023.09.27.559689. doi: 10.1101/2023.09.27.559689. bioRxiv. 2023. PMID: 37808679 Free PMC article. Preprint.
Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron.
Patel A, Kumar S, Lai L, Keen M, Valanparambil R, Chakravarthy C, Laughlin Z, Frank F, Cheedarla N, Verkerke HP, Neish AS, Roback JD, Davis CW, Wrammert J, Sharma A, Ahmed R, Suthar MS, Murali-Krishna K, Chandele A, Ortlund E. Patel A, et al. Among authors: lai l. Cell Rep. 2023 Sep 26;42(9):113150. doi: 10.1016/j.celrep.2023.113150. Epub 2023 Sep 13. Cell Rep. 2023. PMID: 37708028 Free PMC article.
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Lyke KE, et al. NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z. NPJ Vaccines. 2023. PMID: 37433788 Free PMC article.
104 results